Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) today announced The Lancet has published data from a Phase II, double-blind, placebo-controlled, randomized clinical ...

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary ...

List today: Pharming Group N.V. PHAR: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current ...

- Clinical trial follows encouraging results from a Phase II, which showed a statistically significant improvement of kidney injury biomarkers in patients undergoing coronary angiography after ...

Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been dosed in a ...

Pharming's Q2/19 results beat expectations for a second quarter in a row. Turnover is confirming that earlier perceived advantages for competition in the HAE marketplace were misguided.

Pharming Group N.V. This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such ...

Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. announces that the Company’ s 2025 Annual General Meeting of Shareholders will be held on Wednesday June 11, 2025, at 14:00 CEST. The ...

(RTTNews) - Pharming Group N.V. (PHAR) announced, for the full year 2023, total revenues are expected to increase by 19% to approximately $245 million. For 2023, the company expects RUCONEST ...

'Pharming' attacks using sophisticated botnets are growing at an alarming rate, and new forms of authentication are needed to protect e-mail originators and Web sites.

Opinion: New wave of larcenous attempts will involve attacks on Web browsers' address bars to redirect users to bogus Web sites.